SlideShare a Scribd company logo

More Related Content

What's hot

Amy l. Doneen: Imaging & Inflammation: Applying the Evidence to Clinical Prac...
Amy l. Doneen: Imaging & Inflammation: Applying the Evidence to Clinical Prac...Amy l. Doneen: Imaging & Inflammation: Applying the Evidence to Clinical Prac...
Amy l. Doneen: Imaging & Inflammation: Applying the Evidence to Clinical Prac...Cleveland HeartLab, Inc.
 
Sgarbossa criteria for the diagnosis of st elevation myocardial infarction
Sgarbossa criteria for the diagnosis of st elevation myocardial infarctionSgarbossa criteria for the diagnosis of st elevation myocardial infarction
Sgarbossa criteria for the diagnosis of st elevation myocardial infarctionRamachandra Barik
 
Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...
Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...
Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...incucai_isodp
 
Medtronic international the future of cardiac resynchronisation therapy
Medtronic international the future of cardiac resynchronisation therapyMedtronic international the future of cardiac resynchronisation therapy
Medtronic international the future of cardiac resynchronisation therapydrucsamal
 
Atrial fibrillation and anticoagulants
Atrial fibrillation and anticoagulantsAtrial fibrillation and anticoagulants
Atrial fibrillation and anticoagulantsshahhcnt
 
Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.
Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.
Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.Marilyn Mann
 
Identifying super responders to cardiac resynchronization therapy
Identifying super responders to cardiac resynchronization therapyIdentifying super responders to cardiac resynchronization therapy
Identifying super responders to cardiac resynchronization therapydrucsamal
 
Comparative effectiveness of acei and arbi
Comparative effectiveness of acei and arbiComparative effectiveness of acei and arbi
Comparative effectiveness of acei and arbiRamachandra Barik
 
Cardiac resynchronization therapy : Atrial Fibrillation
Cardiac resynchronization therapy : Atrial FibrillationCardiac resynchronization therapy : Atrial Fibrillation
Cardiac resynchronization therapy : Atrial Fibrillationdrucsamal
 

What's hot (18)

PCI & AimRadial 2018 | Coronary Physiology To Guide Interventions - K. Lance ...
PCI & AimRadial 2018 | Coronary Physiology To Guide Interventions - K. Lance ...PCI & AimRadial 2018 | Coronary Physiology To Guide Interventions - K. Lance ...
PCI & AimRadial 2018 | Coronary Physiology To Guide Interventions - K. Lance ...
 
Novedades en fisiopatología y diagnóstico de la IC
Novedades en fisiopatología y diagnóstico de la ICNovedades en fisiopatología y diagnóstico de la IC
Novedades en fisiopatología y diagnóstico de la IC
 
Ensayos clínicos en IC preservada: resultados del PARAGON-HF
Ensayos clínicos en IC preservada: resultados del PARAGON-HFEnsayos clínicos en IC preservada: resultados del PARAGON-HF
Ensayos clínicos en IC preservada: resultados del PARAGON-HF
 
IRON CRT Trial
IRON CRT TrialIRON CRT Trial
IRON CRT Trial
 
ISCHEMIA and ISCHEMIA CKD
ISCHEMIA and ISCHEMIA CKDISCHEMIA and ISCHEMIA CKD
ISCHEMIA and ISCHEMIA CKD
 
Amy l. Doneen: Imaging & Inflammation: Applying the Evidence to Clinical Prac...
Amy l. Doneen: Imaging & Inflammation: Applying the Evidence to Clinical Prac...Amy l. Doneen: Imaging & Inflammation: Applying the Evidence to Clinical Prac...
Amy l. Doneen: Imaging & Inflammation: Applying the Evidence to Clinical Prac...
 
Sgarbossa criteria for the diagnosis of st elevation myocardial infarction
Sgarbossa criteria for the diagnosis of st elevation myocardial infarctionSgarbossa criteria for the diagnosis of st elevation myocardial infarction
Sgarbossa criteria for the diagnosis of st elevation myocardial infarction
 
Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...
Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...
Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...
 
Medtronic international the future of cardiac resynchronisation therapy
Medtronic international the future of cardiac resynchronisation therapyMedtronic international the future of cardiac resynchronisation therapy
Medtronic international the future of cardiac resynchronisation therapy
 
Atrial fibrillation and anticoagulants
Atrial fibrillation and anticoagulantsAtrial fibrillation and anticoagulants
Atrial fibrillation and anticoagulants
 
Esv2n36
Esv2n36Esv2n36
Esv2n36
 
252 statin therapy influence on coronary calcification
252 statin therapy influence on coronary calcification252 statin therapy influence on coronary calcification
252 statin therapy influence on coronary calcification
 
Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.
Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.
Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.
 
Identifying super responders to cardiac resynchronization therapy
Identifying super responders to cardiac resynchronization therapyIdentifying super responders to cardiac resynchronization therapy
Identifying super responders to cardiac resynchronization therapy
 
093 multi slice fast ct
093 multi slice fast ct093 multi slice fast ct
093 multi slice fast ct
 
Comparative effectiveness of acei and arbi
Comparative effectiveness of acei and arbiComparative effectiveness of acei and arbi
Comparative effectiveness of acei and arbi
 
Cardiac resynchronization therapy : Atrial Fibrillation
Cardiac resynchronization therapy : Atrial FibrillationCardiac resynchronization therapy : Atrial Fibrillation
Cardiac resynchronization therapy : Atrial Fibrillation
 
Rsna ac 2011definitiva
Rsna ac 2011definitivaRsna ac 2011definitiva
Rsna ac 2011definitiva
 

Viewers also liked

Viewers also liked (18)

Barth imt
Barth imtBarth imt
Barth imt
 
121 non invasive imaging of coronary arteries
121 non invasive imaging of coronary arteries121 non invasive imaging of coronary arteries
121 non invasive imaging of coronary arteries
 
Slides 1 8
Slides 1 8Slides 1 8
Slides 1 8
 
Atherosclerosis an autoimmune disease
Atherosclerosis an autoimmune diseaseAtherosclerosis an autoimmune disease
Atherosclerosis an autoimmune disease
 
Slides18
Slides18Slides18
Slides18
 
Patrick updown
Patrick updownPatrick updown
Patrick updown
 
Positive remodeling for ralph
Positive remodeling for ralphPositive remodeling for ralph
Positive remodeling for ralph
 
Plaque severity and coronary occlusion
Plaque severity and coronary occlusionPlaque severity and coronary occlusion
Plaque severity and coronary occlusion
 
Slides naqvi
Slides naqviSlides naqvi
Slides naqvi
 
Schwartz debate aha 2002
Schwartz debate aha 2002Schwartz debate aha 2002
Schwartz debate aha 2002
 
Shape symposium slide presentation
Shape symposium slide presentationShape symposium slide presentation
Shape symposium slide presentation
 
Rumberg1
Rumberg1Rumberg1
Rumberg1
 
192 pericardioscopy and pericardial biopsy
192 pericardioscopy and pericardial biopsy192 pericardioscopy and pericardial biopsy
192 pericardioscopy and pericardial biopsy
 
Plaque inflammation in atherosclerotic rabbits
Plaque inflammation in atherosclerotic rabbitsPlaque inflammation in atherosclerotic rabbits
Plaque inflammation in atherosclerotic rabbits
 
185 towards the future cath lab
185 towards the future cath lab185 towards the future cath lab
185 towards the future cath lab
 
Shuzou
ShuzouShuzou
Shuzou
 
Project introduction
Project introductionProject introduction
Project introduction
 
Spect ct -dan berman
Spect ct -dan bermanSpect ct -dan berman
Spect ct -dan berman
 

Similar to Rumberger

214 how can calcium score improve your practice
214 how can calcium score improve your practice214 how can calcium score improve your practice
214 how can calcium score improve your practiceSHAPE Society
 
136 framingham model and coronary events
136 framingham model and coronary events136 framingham model and coronary events
136 framingham model and coronary eventsSHAPE Society
 
093 multi slice fast ct
093 multi slice fast ct093 multi slice fast ct
093 multi slice fast ctSHAPE Society
 
Dr. Jose Luis Zamorano. Evolución no invasiva de la enfermedad aterosclerótica
Dr. Jose Luis Zamorano. Evolución no invasiva de la enfermedad ateroscleróticaDr. Jose Luis Zamorano. Evolución no invasiva de la enfermedad aterosclerótica
Dr. Jose Luis Zamorano. Evolución no invasiva de la enfermedad ateroscleróticaSociedad Española de Cardiología
 
247 ebct vs conventional risk factors
247 ebct vs conventional risk factors247 ebct vs conventional risk factors
247 ebct vs conventional risk factorsSHAPE Society
 
251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calciumSHAPE Society
 
Coronary artery calcium scoring IDoR 2018
Coronary artery calcium scoring IDoR 2018Coronary artery calcium scoring IDoR 2018
Coronary artery calcium scoring IDoR 2018Shawnm Nasih Dawood
 
CT coronary angiography Pay Now, Benefits May Follow
CT coronary angiography Pay Now, Benefits May Follow CT coronary angiography Pay Now, Benefits May Follow
CT coronary angiography Pay Now, Benefits May Follow piuonesto
 
Guidelines For Assessment Of C Visk In Rsymptomatic Adults
Guidelines For Assessment Of C Visk In Rsymptomatic AdultsGuidelines For Assessment Of C Visk In Rsymptomatic Adults
Guidelines For Assessment Of C Visk In Rsymptomatic AdultsJuan Menendez
 

Similar to Rumberger (20)

214 how can calcium score improve your practice
214 how can calcium score improve your practice214 how can calcium score improve your practice
214 how can calcium score improve your practice
 
Vp meeting orlando2003_new template
Vp meeting orlando2003_new templateVp meeting orlando2003_new template
Vp meeting orlando2003_new template
 
136 framingham model and coronary events
136 framingham model and coronary events136 framingham model and coronary events
136 framingham model and coronary events
 
Rumberger 2nd vp symposium 3 6 04
Rumberger 2nd vp symposium 3 6 04Rumberger 2nd vp symposium 3 6 04
Rumberger 2nd vp symposium 3 6 04
 
093 multi slice fast ct
093 multi slice fast ct093 multi slice fast ct
093 multi slice fast ct
 
Dr. Jose Luis Zamorano. Evolución no invasiva de la enfermedad aterosclerótica
Dr. Jose Luis Zamorano. Evolución no invasiva de la enfermedad ateroscleróticaDr. Jose Luis Zamorano. Evolución no invasiva de la enfermedad aterosclerótica
Dr. Jose Luis Zamorano. Evolución no invasiva de la enfermedad aterosclerótica
 
Budoff shape-1105
Budoff shape-1105Budoff shape-1105
Budoff shape-1105
 
247 ebct vs conventional risk factors
247 ebct vs conventional risk factors247 ebct vs conventional risk factors
247 ebct vs conventional risk factors
 
Rumberger vp discussion 11 03
Rumberger vp discussion 11 03Rumberger vp discussion 11 03
Rumberger vp discussion 11 03
 
247 ebct vs conventional risk factors
247 ebct vs conventional risk factors247 ebct vs conventional risk factors
247 ebct vs conventional risk factors
 
251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium
 
251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium
 
Es v2n43
Es v2n43Es v2n43
Es v2n43
 
Aeha2004 crp lppla2newtemplate-koenig
Aeha2004 crp lppla2newtemplate-koenigAeha2004 crp lppla2newtemplate-koenig
Aeha2004 crp lppla2newtemplate-koenig
 
Aeha2004 crp lppla2newtemplate
Aeha2004 crp lppla2newtemplateAeha2004 crp lppla2newtemplate
Aeha2004 crp lppla2newtemplate
 
Coronary artery calcium scoring IDoR 2018
Coronary artery calcium scoring IDoR 2018Coronary artery calcium scoring IDoR 2018
Coronary artery calcium scoring IDoR 2018
 
CT coronary angiography Pay Now, Benefits May Follow
CT coronary angiography Pay Now, Benefits May Follow CT coronary angiography Pay Now, Benefits May Follow
CT coronary angiography Pay Now, Benefits May Follow
 
Shape aha 2005
Shape   aha 2005Shape   aha 2005
Shape aha 2005
 
Guidelines For Assessment Of C Visk In Rsymptomatic Adults
Guidelines For Assessment Of C Visk In Rsymptomatic AdultsGuidelines For Assessment Of C Visk In Rsymptomatic Adults
Guidelines For Assessment Of C Visk In Rsymptomatic Adults
 
Aha 2005 crp cost effectiveness
Aha 2005 crp cost effectivenessAha 2005 crp cost effectiveness
Aha 2005 crp cost effectiveness
 

More from Society for Heart Attack Prevention and Eradication

More from Society for Heart Attack Prevention and Eradication (20)

AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi PresentationAHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
 
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner PresentationAHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
 
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland PresentationAHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
 
AHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen PresentationAHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen Presentation
 
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka PresentationAHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
 
Vu lplaque1 pasterkamp
Vu lplaque1 pasterkampVu lplaque1 pasterkamp
Vu lplaque1 pasterkamp
 
Vulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patientVulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patient
 
Vulnerable plaque overview
Vulnerable plaque overviewVulnerable plaque overview
Vulnerable plaque overview
 
Vulnerable patient talk in poland
Vulnerable patient talk in polandVulnerable patient talk in poland
Vulnerable patient talk in poland
 
Vulnerable patient slides without movies
Vulnerable patient slides without moviesVulnerable patient slides without movies
Vulnerable patient slides without movies
 
Vulnerable patient mar 04
Vulnerable patient mar 04Vulnerable patient mar 04
Vulnerable patient mar 04
 
Vulnerable (thrombogenic blood
Vulnerable (thrombogenic bloodVulnerable (thrombogenic blood
Vulnerable (thrombogenic blood
 
Vuln shape aha 2005
Vuln shape aha 2005Vuln shape aha 2005
Vuln shape aha 2005
 
Vuln plaque poster burke
Vuln plaque poster burkeVuln plaque poster burke
Vuln plaque poster burke
 
Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-
 
Vp watch editorial_slide25
Vp watch editorial_slide25Vp watch editorial_slide25
Vp watch editorial_slide25
 
Vp watch editorial_slide25short-
Vp watch editorial_slide25short-Vp watch editorial_slide25short-
Vp watch editorial_slide25short-
 
Vp watch2002
Vp watch2002Vp watch2002
Vp watch2002
 
Vp symposium31602
Vp symposium31602Vp symposium31602
Vp symposium31602
 
Vpschoenhagen
VpschoenhagenVpschoenhagen
Vpschoenhagen
 

Recently uploaded

Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedSBL DIGITAL
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCEShubhadip Ghosh
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeQuick MedTalk
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionZeinabEmad3
 
Thyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersThyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersSai Sailesh Kumar Goothy
 
Ovarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxOvarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxSizan Thapa
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxTina Purnat
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)chahattyagi200
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxAbdirahmanWaseem
 
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxSizan Thapa
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)pranavguleria2
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...DUY NGUYEN PHUC
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptKavitha Krishnan
 
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Dr. Dheeraj Kumar
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyYves Sucaet
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptxRajendra Dev Bhatt
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfHongBiThi1
 

Recently uploaded (20)

Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCE
 
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), Addiction
 
Thyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersThyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disorders
 
Oral disorders .pptx
Oral disorders .pptxOral disorders .pptx
Oral disorders .pptx
 
Ovarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxOvarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptx
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptx
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptx
 
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
 
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
 
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathology
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
 

Rumberger

  • 1. Vulnerable Plaque SymposiumVulnerable Plaque Symposium Patients with High CRP & HighPatients with High CRP & High CT Calcium Score are at Higher Risk:CT Calcium Score are at Higher Risk: How Can Calcium ScoreHow Can Calcium Score Improve Your Practice?Improve Your Practice? John A. Rumberger, PhD, MD, FACCJohn A. Rumberger, PhD, MD, FACC Clinical Professor of Medicine, Ohio State UniversityClinical Professor of Medicine, Ohio State University Medical DirectorMedical Director Physician’s Prevention and Wellness CenterPhysician’s Prevention and Wellness Center Columbus, OhioColumbus, Ohio Chicago, ILChicago, IL March 29, 2003March 29, 2003© 2003 John A Rumberger, MD
  • 2. 1.25 1.6 1.6 1.8 2.15 2.35 2.5 5 0 2 4 6 8 10 Lp(a) Homocysteine TC Fibr t-PA Ag TC/HDL hs-CRP hs-CRP + TC/HDL RR in men from the Physicians Health Study Risk of MI in Apparently Healthy PeopleRisk of MI in Apparently Healthy People Values in the Upper Quartile Compared to Lowest Quartile
  • 3. hs C-Reactive Proteinhs C-Reactive Protein AtAt PRESENTPRESENT the following has been established:the following has been established: o Values in the upper tercile (or quartile) confer a 2+ risk MI/SCDValues in the upper tercile (or quartile) confer a 2+ risk MI/SCD o Marker likely for “endothelial dysfunction”Marker likely for “endothelial dysfunction” o May have a role in “promoting atherogenesis”May have a role in “promoting atherogenesis” o Values altered by:Values altered by: Increased By Decreased ByIncreased By Decreased By Elevated BP ETOH consumptionElevated BP ETOH consumption BMI Aerobic exerciseBMI Aerobic exercise Metabolic syndrome Weight lossMetabolic syndrome Weight loss Hormone use Medications:Hormone use Medications: Chronic infections statins, fibrates,Chronic infections statins, fibrates, Chronic inflammation niacinChronic inflammation niacin
  • 4. hs C-Reactive Proteinhs C-Reactive Protein o May or may not be related to the severity or extent of diseaseMay or may not be related to the severity or extent of disease o This could be due to differences in chronicity or “pattern”This could be due to differences in chronicity or “pattern” o CRP may be more related to “acceleration of atherosclerosis”CRP may be more related to “acceleration of atherosclerosis” rather than its extentrather than its extent
  • 5. VTVT VT = “vulnerable threshold”VT = “vulnerable threshold” ““vulnerability”vulnerability” TimeTime Patient APatient A Patient BPatient B MI/SCDMI/SCD The “Vulnerable Threshold” CRPCRP CRPCRP CRPCRP © © 2003 John A Rumberger, MD
  • 6. CT Coronary Artery CalciumCT Coronary Artery Calcium No CalcificationNo Calcification Severe CalcificationSevere Calcification Left Main LAD LCX AoAo LALA PAPA
  • 7. Coronary Calcium Area by EBT andCoronary Calcium Area by EBT and Coronary Artery Plaque AreaCoronary Artery Plaque Area 0 2 4 6 8 10 12 14 16 0 2 4 6 8 Square Root Sum of Calcium Areas SquareRootSumof PlaqueAreas Rumberger, Circ 1995:92:2157-62 n = 38n = 38 r = 0.90r = 0.90 p < .001p < .001
  • 8. No. of coronary segments/pt. with plaques (IVUS) 0 1 2 3 4 5 6 7 No. of calcified coronary segments/pt. (EBCT) 0 1 2 3 4 5 6 7 Y = -0.67 + (0.90 * X) r = 0.86 p < 0.0001 N = 40 patients total of 222 coronary segments examined Acute Coronary Syndrome and Non-Obstructive CADAcute Coronary Syndrome and Non-Obstructive CAD # of segments with EBCT calcium vs. # of segments with any plaque# of segments with EBCT calcium vs. # of segments with any plaque Schmermund et alSchmermund et al AJC 1998; 81:AJC 1998; 81: 141-146141-146
  • 9. EBT and Coronary Artery CalciumEBT and Coronary Artery Calcium  Define the extent of ASO disease?Define the extent of ASO disease? YESYES  The amount of calciumThe amount of calcium correlates DIRECTLYcorrelates DIRECTLY toto the amount of measurable coronary disease by:the amount of measurable coronary disease by: 1) direct histopathologic comparison1) direct histopathologic comparison 2) with intravascular ultrasound2) with intravascular ultrasound
  • 10. 3 4.4 8.8 0 2 4 6 8 10 Score 0 Score 1-15 Score 16- 80 Score 81- 270 Score >271 Relative Risk for Future CV Events using EBCT:Relative Risk for Future CV Events using EBCT: 926 initially asymptomatic patients926 initially asymptomatic patients 1st Quartile1st Quartile 2nd Quartile2nd Quartile 3rd Quartile3rd Quartile 4th Quartile4th Quartile * AdjustedAdjusted for age, gender, hypertension, past/current smoking, and diabetesfor age, gender, hypertension, past/current smoking, and diabetes Wong and Detrano, et al [Am J Cardiol 2000;86:495-498Wong and Detrano, et al [Am J Cardiol 2000;86:495-498 RelativeRisk(RR)RelativeRisk(RR)
  • 11. Prediction of MI/SCD in Asymptomatic Patients:Prediction of MI/SCD in Asymptomatic Patients: EBTEBT Raggi et al AHJ 2001;141:193-199Raggi et al AHJ 2001;141:193-199 0.36 0.51 0.71 0.99 1.38 1.92 2.64 3.62 4.9 6.54 0 1 2 3 4 5 6 7 0 10 20 30 40 50 60 70 80 90 Percentile Rank for Baseline EBCT Calcium ScorePercentile Rank for Baseline EBCT Calcium Score 676 initially asymptomatic patients676 initially asymptomatic patients 3232++7 months f/u7 months f/u AnnualAnnual AbsoluteAbsolute RiskRisk
  • 12. EBT Calcium Score ProgressionEBT Calcium Score Progression and Coronary Eventsand Coronary Events 0 1.5 6.45 0 1 2 3 4 5 6 7 AnnualEventRates No progression 1-20% Increase >20% Increase Annual CAC Score ChangeAnnual CAC Score Change ““High” risk by NCEP criteriaHigh” risk by NCEP criteria Shah, Circulation 2000Shah, Circulation 2000
  • 13. Coronary Artery CalcificationCoronary Artery Calcification AtAt PRESENTPRESENT the following has been established:the following has been established: o Coronary calcium IS Atherosclerosis o The magnitude of the calcium score relates to the severity of ASO disease o The calcium score as well as the percentile rank provide information in which to view risk factors, rather than the other way around o The data on examining progression of CAD with CT are consistent with the potential for the calcium score/rank to be used as the “goal” of therapy
  • 14. RR of MI/SCD: EBT Score and hs-CRP 0 2 4 6 8 High CAC Med. CAC Low CAC Low hs-CRP High hs-CRP Park et al. Circ. 2002;106-2073-2077
  • 15. Prediction of MI/SCD in Asymptomatic Patients:Prediction of MI/SCD in Asymptomatic Patients: EBTEBT 0 1 2 3 4 5 6 7 0 10 20 30 40 50 60 70 80 90 Percentile Rank for Baseline EBCT Calcium ScorePercentile Rank for Baseline EBCT Calcium Score LowLow RiskRisk IntermediateIntermediate RiskRisk HighHigh RiskRisk
  • 16. Prediction of MI/SCD in Asymptomatic Patients:Prediction of MI/SCD in Asymptomatic Patients: EBTEBT 0 1 2 3 4 5 6 7 0 10 20 30 40 50 60 70 80 90 Percentile Rank for Baseline EBCT Calcium ScorePercentile Rank for Baseline EBCT Calcium Score LowLow RiskRisk IntermediateIntermediate RiskRisk HighHigh RiskRisk CRP CRP
  • 17. Clinical Questions in PreventionClinical Questions in Prevention In the asymptomatic individual How aggressive should I be? How closely should I follow up?
  • 18. hs-CRP CAC Range Level of Aggression, f/u < 1 mg/L > 1-3 mg/L > 3 mg/L hs-CRP & CAC Scoringhs-CRP & CAC Scoring Value Range Percentile Range Aggression Clinical f/u Low Low Low Mod. Mod. Mod. High High High <25th Low >25th -<75th Intermed. >75th High <25th Low >25th -<75th Intermed. >75th High <25th Low >25th -<75th Intermed. >75th High Primary Routine Primary Routine Secondary Close Primary Routine Primary Close Secondary Close Primary Close Secondary Close Secondary Close
  • 19. hs-CRP & CAC Scoringhs-CRP & CAC Scoring In “intermediate” risk asymptomatic individualsIn “intermediate” risk asymptomatic individuals CAC Scanning with CTCAC Scanning with CT && hs-CRP testinghs-CRP testing areare ComplementaryComplementary to each otherto each other and the combination of bothand the combination of both can be used to refinecan be used to refine Clinical-Decision making in such patientsClinical-Decision making in such patients